Onco Actu du 21 février 2018

	1. Biologie
In study, Stanford researchers analyze ovarian cancer cells at unprecedented level of specificity [Stanford Medicine] Fantl and her colleagues identified a subset of tumor cells that co-express three proteins — vimentin, HE4 and cMyc — often found on metastatic cells. Women whose tumors had an increased number of these cells were at a high risk of early relapse, the researchers found.
	2.11 Etiologie - Alimentation
Research Check: will eating ‘ultra-processed’ foods give you cancer? [The Conversation] The data comes from an observational cohort study and therefore cannot prove causation. There will never be a randomised controlled trial (comparing one group with placebo) of whether or not eating ultra-processed foods causes cancer because you cannot ethically randomise people to a lifetime consuming very high intakes of these foods.
	3.1 Prévention - Tabac
ASCO Statement on JAMA Internal Medicine’s Cigarette, Cigar, and Pipe Use Mortality Risk Study [ASCO] This research further highlights the fact that combustible tobacco products cause many types of cancer. It also emphasizes why the Food and Drug Administration should use its authority to regulate cigars and pipe and hookah tobacco.
Popular push for Austrian smoking ban gathers pace [Reuters] More than 200,000 Austrians have signed a petition calling for a ban on smoking in bars and restaurants, campaign organisers said - using one of the new right-wing government’s signature policies to undermine another.
	4.1 Dép., diag. & prono. - Prostate
NCCN Guidelines Broadly Endorse Biomarker Testing in Prostate Cancer [Myriad] Prolaris®, myRisk® Hereditary Cancer, and myChoice® HRD Testing Are Appropriate For a Total of 200,000 Prostate Cancer Patients per Year.
	4.13 Dép., diag. & prono. - Peau
DermTech’s Late Breaking Abstract Presented at AAD Validates Gene Expression Against High Risk DNA Mutations Providing Objective Information for the Diagnosis of Melanoma [DermTech] The data provides the foundation for launching Nevome, DermTech’s second “adhesive patch skin biopsy” product, to help assess pigmented lesions suspicious for melanoma.
	4.9 Dép., diag. & prono. - Sein
MRI Technique Differentiates Benign Breast Lesions from Malignancies [RSNA] Should the results hold in larger trials, the model has potential advantages in the clinic beyond its ability to reduce unnecessary biopsies in women with BI-RADS 4 lesions. The software algorithm makes the assessment reader-independent, ensuring that its accuracy is maintained across different imaging facilities.
	5.1 Traitements - Pré-clinique
Can Oxygen “Microbubbles” Make Radiation Therapy More Effective? [NCI] In the NCI-supported study, researchers used these “microbubbles” and ultrasound waves to increase the amount of oxygen within tumors. This treatment, they found, greatly improved the ability of radiation therapy to slow breast tumors growing in the mice.
	5.10 Traitements - Essais
New study raises questions about early-stage cancer therapies for children [STAT] Scientists conducted a systematic review and meta-analysis of Phase 1 clinical trials involving children with cancer and found, on average, only 1 in 10 will see their condition improve. About 1 in 50 children will die from complications related to the drug.
	5.12.10 Immunothérapies - Fusions et acquisitions
Merck and Viralytics Announce Acquisition Agreement, Expanding Merck’s Leading Immuno-Oncology Pipeline [Merck] CAVATAK is based on Viralytics’s proprietary formulation of an oncolytic virus (Coxsackievirus Type A21) that has been shown to preferentially infect and kill cancer cells. CAVATAK is currently being evaluated in multiple Phase 1 and Phase 2 clinical trials, both as an intratumoral and intravenous agent, including in combination with Merck’s KEYTRUDA® (pembrolizumab), an anti-PD-1 therapy
	5.12.6 Immunothérapies - AMM
AstraZeneca's Imfinzi breaks new I-O ground with landmark $1B lung cancer nod [FiercePharma] In the all-important first-line lung cancer market, Imfinzi’s future is uncertain. After fielding a high-profile trial flop last summer, the British drugmaker is waiting for overall survival data from the Mystic trial, which pairs Imfinzi with its CTLA4 candidate tremelimumab.
	5.2.1 Pharma - Partenariats
Institut Curie, CNRS, AP-HP and ElsaLys Biotech sign an exclusive licence agreement to develop an anti-TYRO3 therapeutic antibody [Institut Curie] Specifically, this new collaboration will demonstrate in vitro that the blocking of TYRO3 activity by human anti-TYRO3 antibodies generated by ELSALYS BIOTECH results in functional inhibition of survival in tumor cell models (including bladder leiomyosarcomas). It will also demonstrate in vivo the anti-tumor properties of the anti-TYRO3 candidate antibody in xenograft models of tumor lines.
	5.3.4 Traitements - AMM (FDA, EMA,...)
New Therapeutic Approved by FDA to Treat Prostate Cancer [Cancer Research Catalyst] Apalutamide is another second-generation antihormone agent. The first information about the discovery and preclinical development of the agent, which was called ARN-509 at the time, was published in the AACR journal Cancer Research six years ago.
	5.4 Traitements - Economie
NICE recommends thyroid cancer drug trio for NHS use [Pharmafile] Ipsen’s Cometriq (cabozantinib), Bayer’s Nexavar (sorafenib), and Eisai’s Lenvima (lenvatinib). The former two were previously only available via the Cancer Drugs Fund (CDF), and the latter sees approval after delays of more than two years.
	6.1 Observation
Survivors of blood or marrow transplantation are likely to experience cognitive impairment [University of Alabama] In analyzing the data, at three years post-transplant, evidence of cognitive impairment was present in 35.7 percent of allogeneic recipients.
	6.4 Médico-éco
Hospital Charges For Outpatient Cancer Care Highly Variable, Medicare Billing Records Show [Johns Hopkins] “Cancer patients shouldn’t be put into household bankruptcy just because a hospital inflates a bill well above what an insurance company would pay for the exact same service.”
The U.S. healthcare system needs more skills for paying bills, study shows [LA Times] Healthcare in the United States is really expensive, and one of the reasons is that managing healthcare bills is really, really expensive. Just how expensive? At one large academic medical center, the cost of collecting payments for a single primary-care doctor is upward of $99,000 a year.
	6.6 Publications
Not So Many Uncited Papers, Actually [In the Pipeline] The ten-year uncited rate across all disciplines, minus self-citation, is about 18%. But another thing that such studies have uncovered is that this rate has been dropping for many years.
Prestigious Science Journals Struggle to Reach Even Average Reliability [Frontiers in Human Neuroscience] Comparing higher with lower ranked journals, two main conclusions can be drawn: (1) experiments reported in high-ranking journals are no more methodologically sound than those published in other journals; and (2) experiments reported in high-ranking journals are often less methodologically sound than those published in other journals.
	6.7.1 Bioinformatique
Deep learning for biology [Nature] A popular artificial-intelligence method provides a powerful tool for surveying and classifying biological data. But for the uninitiated, the technology poses significant difficulties.
	6.7.2 Applis
Could Apple’s move into EHR allow pharma to connect directly to patients? [FiercePharma] In much the same way that Apple suggests music to you through iTunes, they could be suggesting health interventions to you through your Health Record app.
	6.7.3 DMP
EHRs do not lower administrative billing costs, study finds [Modern Healthcare] "After investing more than $30 billion in health IT, we haven't improved the administrative efficiency."
EHR interoperability, connectivity a big challenge around globe new study finds [Healthcare IT News] Eighty-three percent of EHR users in Europe outside the United Kingdom indicated frustration with country-specific and local vendors that typically serve only one country with limited components, such as coding, scheduling and results reporting.